Akebia Therapeutics

AKBA Rare disease Lead: Approved 5 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

AKB-097 Ph2 start2H 2026AKB-097 Ph2 start, 2H 2026, routine
Vafseo VOCAL topline4Q 2026Vafseo VOCAL topline, 4Q 2026, thesis-defining
AKB-9090 Ph1 toplineearly 2027AKB-9090 Ph1 topline, early 2027, major
AKB-097 readout2027AKB-097 readout, 2027, material
Term loan financingJan 1, 2027Term loan financing, Jan 1, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Vafseo

vadadustat

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

Anemia Due to Chronic Kidney Disease Approved oral NCT02648347

Auryxia

ferric citrate

Small Molecule

Hyperphosphatemia Approved oral NCT04922645
Iron Deficiency Anemia Approved oral NCT04922645

praliciguat

Small Molecule Target: sGC, soluble guanylate cyclase

Focal Segmental Glomerulosclerosis Phase 2 oral Cyclerion Therapeutics NCT07268638

ebribafusp

AKB-097 · ADX-097

Protein Target: C3d, Factor H

AKB-9090

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

AKB-10108

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

Retinopathy of Prematurity Preclinical

Biotech Distilled coverage (5)

2026-08-06 UPDATE: Akebia Therapeutics (AKBA) - The Auryxia Curve, and a Bigger Problem in the Footnotes 🔒 Paid
2026-08-04 UPDATE: Akebia Therapeutics (AKBA) - The Smart Bomb Gets a Name 🔒 Paid
2026-06-30 UPDATE: Akebia Therapeutics (AKBA) - VOICE Stops Early 🔒 Paid
2026-05-08 UPDATE: Akebia Therapeutics (AKBA) - The Receipts Arrive 🔒 Paid
2026-03-04 Akebia (AKBA): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.